环状RNA在卵巢癌中的研究新进展

doi:10.12280/gjfckx.20200530

摘要/Abstract

摘要：

环状RNA（circular RNAs,circRNA）是具有多种特性和病理生理功能的非编码RNA网络热点成员。circRNA在表观遗传、转录和转录后调控水平上发挥作用。目前经过验证的涉及卵巢癌的内源性circRNA数量持续增加,且多种circRNA表达与卵巢癌的发生、侵袭和转移有关。此外,circRNA的异常表达也与卵巢癌的分期、肿瘤体积、分化和转移密切相关。由于circRNA高稳定性、高度保守并且具有组织特异性表达模式,其可能成为诊断卵巢癌的潜在标志物。本文综述了卵巢癌相关circRNA的研究,提出了其对卵巢癌发生的影响,及其作为诊断和预后生物标志物和作为卵巢癌治疗靶点的潜在价值,并且探讨了circRNA对卵巢癌化疗药物耐药性的影响。最后,讨论了卵巢癌相关circRNA在临床上的潜力和未来研究方向。

关键词: 环状RNA, 卵巢肿瘤, 生物标记, 肿瘤, 诊断, 治疗

Abstract:

Circular RNAs (circRNA) are hotspot members of non-coding RNA networks, which have a variety of characteristics and pathophysiological functions. CircRNA plays roles in epigenetic, transcriptional, and post-transcriptional regulation. At present, the number of validated endogenous circRNA involved in ovarian cancer continues increasing and many circRNA expressions are related to the occurrence, invasion and metastasis of ovarian cancer. In addition, the abnormal expression of circRNA is also closely related to the stage, volume of tumor, differentiation and metastasis of ovarian cancer. Because of their high stability, highly conserved, and tissue-specific expression patterns, circRNA may become potential markers of ovarian cancer for the diagnosis. This article reviews the current research reports of circRNA related to ovarian cancer, proposes its impact on the occurrence of ovarian cancer and its potential value as a diagnostic and prognostic biomarker and as a therapeutic target for ovarian cancer, and explores circRNA′s impacts of chemotherapy resistance for ovarian cancer. Finally, the clinical potential and future research directions of circRNA related to ovarian cancer are discussed.

Key words: Circular RNAs, Ovarian neoplasms, Biomarkers, tumor, Diagnosis, Therapy

刘艳, 鲁鹏, 候丽盈, 李佩玲. 环状RNA在卵巢癌中的研究新进展[J]. 国际妇产科学杂志, 2021, 48(1): 61-65.

LIU Yan, LU Peng, HOU Li-ying, LI Pei-ling. New Research Progress of CircRNA in Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(1): 61-65.

参考文献 50

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(1):7-30. doi: 10.3322/caac.21442. doi: 10.3322/caac.21442 pmid: 29313949
[2]	Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(4):284-296. doi: 10.3322/caac.21456. doi: 10.3322/caac.21456 pmid: 29809280
[3]	Li QH, Liu Y, Chen S, et al. circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge[J]. Biomed Pharmacother, 2019,114:108832. doi: 10.1016/j.biopha.2019.108832. doi: 10.1016/j.biopha.2019.108832 pmid: 30965236
[4]	Pokhriyal R, Hariprasad R, Kumar L, et al. Chemotherapy Resistance in Advanced Ovarian Cancer Patients[J]. Biomark Cancer, 2019, 11:1179299X19860815. doi: 10.1177/1179299X19860815. doi: 10.1177/1179299X17710944 pmid: 28607544
[5]	Chen LL, Yang L. Regulation of circRNA biogenesis[J]. RNA Biol, 2015,12(4):381-388. doi: 10.1080/15476286.2015.1020271. doi: 10.1080/15476286.2015.1020271 pmid: 25746834
[6]	Suzuki H, Tsukahara T. A view of pre-mRNA splicing from RNase R resistant RNAs[J]. Int J Mol Sci, 2014,15(6):9331-9342. doi: 10.3390/ijms15069331. doi: 10.3390/ijms15069331 pmid: 24865493
[7]	Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats[J]. RNA, 2013,19(2):141-157. doi: 10.1261/rna.035667.112. doi: 10.1261/rna.035667.112
[8]	Han B, Chao J, Yao H. Circular RNA and its mechanisms in disease: From the bench to the clinic[J]. Pharmacol Ther, 2018,187:31-44. doi: 10.1016/j.pharmthera.2018.01.010. doi: 10.1016/j.pharmthera.2018.01.010 pmid: 29406246
[9]	Rybak-Wolf A, Stottmeister C, Glažar P, et al. Circular RNAs in the Mammalian Brain Are Highly Abundant,Conserved,and Dynamically Expressed[J]. Mol Cell, 2015,58(5):870-885. doi: 10.1016/j.molcel.2015.03.027. doi: 10.1016/j.molcel.2015.03.027 pmid: 25921068
[10]	Qu S, Yang X, Li X, et al. Circular RNA: A new star of noncoding RNAs[J]. Cancer Lett, 2015,365(2):141-148. doi: 10.1016/j.canlet.2015.06.003. doi: 10.1016/j.canlet.2015.06.003 pmid: 26052092
[11]	Gan X, Zhu H, Jiang X, et al. CircMUC16 promotes autophagy of epithelial ovarian cancer via interaction with ATG13 and miR-199a[J]. Mol Cancer, 2020,19(1):45. doi: 10.1186/s12943-020-01163-z. doi: 10.1186/s12943-020-01163-z pmid: 32111227
[12]	Deng G, Zhou X, Chen L, et al. High expression of ESRP1 regulated by circ-0005585 promotes cell colonization in ovarian cancer[J]. Cancer Cell Int, 2020,20:174. doi: 10.1186/s12935-020-01254-3. doi: 10.1186/s12935-020-01254-3 pmid: 32467669
[13]	Zhao Y, Hu Y, Shen Q, et al. CircRNA_MYLK promotes malignant progression of ovarian cancer through regulating microRNA-652[J]. Eur Rev Med Pharmacol Sci, 2020,24(10):5281-5291. doi: 10.26355/eurrev_202005_21310. doi: 10.26355/eurrev_202005_21310 pmid: 32495861
[14]	Zhao Z, Ji M, Wang Q, et al. Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression[J]. Mol Ther Nucleic Acids, 2019,18:24-33. doi: 10.1016/j.omtn.2019.07.012. doi: 10.1016/j.omtn.2019.07.012 pmid: 31479922
[15]	Zhang S, Cheng J, Quan C, et al. circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252[J]. Mol Ther Nucleic Acids, 2020,19:718-730. doi: 10.1016/j.omtn.2019.12.005. doi: 10.1016/j.omtn.2019.12.005 pmid: 31945729
[16]	Chen LL. The biogenesis and emerging roles of circular RNAs[J]. Nat Rev Mol Cell Biol, 2016,17(4):205-211. doi: 10.1038/nrm.2015.32. doi: 10.1038/nrm.2015.32 pmid: 26908011
[17]	Xu S, Zhou L, Ponnusamy M, et al. A comprehensive review of circRNA: from purification and identification to disease marker potential[J]. PeerJ, 2018,6:e5503. doi: 10.7717/peerj.5503. doi: 10.7717/peerj.5503 pmid: 30155370
[18]	Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. circRNA biogenesis competes with pre-mRNA splicing[J]. Mol Cell, 2014,56(1):55-66. doi: 10.1016/j.molcel.2014.08.019. doi: 10.1016/j.molcel.2014.08.019 pmid: 25242144
[19]	Starke S, Jost I, Rossbach O, et al. Exon circularization requires canonical splice signals[J]. Cell Rep, 2015,10(1):103-111. doi: 10.1016/j.celrep.2014.12.002. doi: 10.1016/j.celrep.2014.12.002 pmid: 25543144
[20]	Zhang XO, Dong R, Zhang Y, et al. Diverse alternative back-splicing and alternative splicing landscape of circular RNAs[J]. Genome Res, 2016,26(9):1277-1287. doi: 10.1101/gr.202895.115. doi: 10.1101/gr.202895.115 pmid: 27365365
[21]	Dong Y, He D, Peng Z, et al. Circular RNAs in cancer: an emerging key player[J]. J Hematol Oncol, 2017,10(1):2. doi: 10.1186/s13045-016-0370-2. doi: 10.1186/s13045-016-0370-2 pmid: 28049499
[22]	Hansen TB, Wiklund ED, Bramsen JB, et al. miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNA[J]. EMBO J, 2011,30(21):4414-4422. doi: 10.1038/emboj.2011.359. doi: 10.1038/emboj.2011.359
[23]	Zang J, Lu D, Xu A. The interaction of circRNAs and RNA binding proteins: An important part of circRNA maintenance and function[J]. J Neurosci Res, 2020,98(1):87-97. doi: 10.1002/jnr.24356. doi: 10.1002/jnr.24356 pmid: 30575990
[24]	Dragomir M, Calin GA. Circular RNAs in Cancer-Lessons Learned From microRNAs[J]. Front Oncol, 2018,8:179. doi: 10.3389/fonc.2018.00179. doi: 10.3389/fonc.2018.00179 pmid: 29911069
[25]	Zhang Y, Zhang XO, Chen T, et al. Circular intronic long noncoding RNAs[J]. Mol Cell, 2013,51(6):792-806. doi: 10.1016/j.molcel.2013. 08.017. doi: 10.1016/j.molcel.2013.08.017 pmid: 24035497
[26]	Panda AC, Grammatikakis I, Munk R, et al. Emerging roles and context of circular RNAs[J]. Wiley Interdiscip Rev RNA, 2017, 8(2):10.1002/wrna. doi: 10.1002/wrna.1386. doi: 10.1002/wrna.1381 pmid: 27440103
[27]	Pan J, Meng X, Jiang N, et al. Insights into the Noncoding RNA-encoded Peptides[J]. Protein Pept Lett, 2018,25(8):720-727. doi: 10.2174/0929866525666180809142326. doi: 10.2174/0929866525666180809142326 pmid: 30091402
[28]	Zhang M, Xia B, Xu Y, et al. Circular RNA (hsa_circ_0051240) promotes cell proliferation, migration and invasion in ovarian cancer through miR-637/KLK4 axis[J]. Artif Cells Nanomed Biotechnol, 2019,47(1):1224-1233. doi: 10.1080/21691401.2019.1593999. doi: 10.1080/21691401.2019.1593999 pmid: 30945557
[29]	Xie J, Wang S, Li G, et al. circEPSTI1 regulates ovarian cancer progression via decoying miR-942[J]. J Cell Mol Med, 2019,23(5):3597-3602. doi: 10.1111/jcmm.14260. doi: 10.1111/jcmm.14260 pmid: 30887698
[30]	Chen H, Mao M, Jiang J, et al. Circular RNA CDR1as acts as a sponge of miR-135b-5p to suppress ovarian cancer progression[J]. Onco Targets Ther, 2019,12:3869-3879. doi: 10.2147/OTT.S207938. doi: 10.2147/OTT.S207938 pmid: 31190886
[31]	Huang XY, Huang ZL, Xu YH, et al. Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-100338/miR-141-3p pathway in hepatitis B-related hepatocellular carcinoma[J]. Sci Rep, 2017,7(1):5428. doi: 10.1038/s41598-017-05432-8. doi: 10.1038/s41598-017-05432-8 pmid: 28710406
[32]	Zhou B, Yu JW. A novel identified circular RNA, circRNA_010567,promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-β1[J]. Biochem Biophys Res Commun, 2017,487(4):769-775. doi: 10.1016/j.bbrc.2017.04.044. pmid: 28412345
[33]	Mak CS, Yung MM, Hui LM, et al. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis[J]. Mol Cancer, 2017,16(1):11. doi: 10.1186/s12943-017-0582-2. doi: 10.1186/s12943-017-0582-2 pmid: 28095864
[34]	van Jaarsveld MT, Helleman J, Boersma AW, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells[J]. Oncogene, 2013,32(36):4284-4293. doi: 10.1038/onc.2012.433. doi: 10.1038/onc.2012.433
[35]	Sehouli J, Senyuva F, Fotopoulou C, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer[J]. J Surg Oncol, 2009,99(7):424-427. doi: 10.1002/jso.21288. doi: 10.1002/jso.21288 pmid: 19365809
[36]	Sanger HL, Klotz G, Riesner D, et al. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures[J]. Proc Natl Acad Sci U S A, 1976,73(11):3852-3856. doi: 10.1073/pnas.73.11.3852. doi: 10.1073/pnas.73.11.3852 pmid: 1069269
[37]	Ahmed I, Karedath T, Andrews SS, et al. Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma[J]. Oncotarget, 2016,7(24):36366-36381. doi: 10.18632/oncotarget.8917. doi: 10.18632/oncotarget.8917 pmid: 27119352
[38]	Zhang P, Zhu J, Zheng Y, et al. miRNA-574-3p inhibits metastasis and chemoresistance of epithelial ovarian cancer (EOC) by negatively regulating epidermal growth factor receptor (EGFR)[J]. Am J Transl Res, 2019,11(7):4151-4165. pmid: 31396325
[39]	Chen X, Mangala LS, Mooberry L, et al. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer[J]. Oncogene, 2019,38(33):6095-6108. doi: 10.1038/s41388-019-0862-y. doi: 10.1038/s41388-019-0862-y pmid: 31289363
[40]	Clark AS, West K, Streicher S, et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells[J]. Mol Cancer Ther, 2002,1(9):707-717. pmid: 12479367
[41]	Mabuchi S, Kuroda H, Takahashi R, et al. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer[J]. Gynecol Oncol, 2015,137(1):173-179. doi: 10.1016/j.ygyno.2015.02.003. doi: 10.1016/j.ygyno.2015.02.003 pmid: 25677064
[42]	Zhang L, Zhou Q, Qiu Q, et al. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer[J]. Mol Cancer, 2019,18(1):144. doi: 10.1186/s12943-019-1080-5. doi: 10.1186/s12943-019-1080-5 pmid: 31623606
[43]	Wang W, Wang J, Zhang X, et al. Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer[J]. Onco Targets Ther, 2019,12:7451-7457. doi: 10.2147/OTT.S220700. doi: 10.2147/OTT.S220700 pmid: 31686850
[44]	Fan CM, Wang JP, Tang YY, et al. circMAN1A2 could serve as a novel serum biomarker for malignant tumors[J]. Cancer Sci, 2019,110(7):2180-2188. doi: 10.1111/cas.14034. doi: 10.1111/cas.14034 pmid: 31046163
[45]	Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges[J]. Nature, 2013,495(7441):384-388. doi: 10.1038/nature11993. doi: 10.1038/nature11993
[46]	Liu X, Abraham JM, Cheng Y, et al. Synthetic Circular RNA Functions as a miR-21 Sponge to Suppress Gastric Carcinoma Cell Proliferation[J]. Mol Ther Nucleic Acids, 2018,13:312-321. doi: 10.1016/j.omtn.2018.09.010. doi: 10.1016/j.omtn.2018.09.010 pmid: 30326427
[47]	Wang Z, Ma K, Cheng Y, et al. Synthetic circular multi-miR sponge simultaneously inhibits miR-21 and miR-93 in esophageal carcinoma[J]. Lab Invest, 2019,99(10):1442-1453. doi: 10.1038/s41374-019-0273-2. doi: 10.1038/s41374-019-0273-2 pmid: 31217510
[48]	Shah MY, Ferrajoli A, Sood AK, et al. microRNA Therapeutics in Cancer - An Emerging Concept[J]. EBioMedicine, 2016,12:34-42. doi: 10.1016/j.ebiom.2016.09.017. doi: 10.1016/j.ebiom.2016.09.017 pmid: 27720213
[49]	Petrescu G, Sabo AA, Torsin LI, et al. MicroRNA based theranostics for brain cancer: basic principles[J]. J Exp Clin Cancer Res, 2019,38(1):231. doi: 10.1186/s13046-019-1180-5. doi: 10.1186/s13046-019-1180-5 pmid: 31142339
[50]	Kristensen LS, Andersen MS, Stagsted L, et al. The biogenesis, biology and characterization of circular RNAs[J]. Nat Rev Genet, 2019,20(11):675-691. doi: 10.1038/s41576-019-0158-7. doi: 10.1038/s41576-019-0158-7 pmid: 31395983